Amarin Corporation PLC (AMRN) vs Biogen Inc. (BIIB)
Amarin Corporation PLC and Biogen Inc. are both Drug Manufacturers General companies. Biogen Inc. is the larger, with a market value of $33.5B against $283.6M — 118.2× the size. Amarin Corporation PLC has negative trailing earnings, so its P/E is not meaningful; Biogen Inc. trades at 40.1×. Biogen Inc. grew revenue faster over the last twelve months: 0.31% against −15.1%. Biogen Inc. has the higher net margin (8.32% vs −14.6%) and the higher return on invested capital (3.11% vs −19.8%). Across the 21 metrics below, Biogen Inc. leads on 13 and Amarin Corporation PLC on 8.
Valuation
Profitability
| Metric | AMRN | BIIB | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 41.96% | 73.99% | 72.77% |
| Operating margin | (21.89%) | 12.35% | 18.90% |
| Net margin | (14.56%) | 8.32% | 8.27% |
| Free cash flow margin | 8.36% | 25.33% | 17.25% |
| Return on equity | (5.97%) | 4.58% | 6.97% |
| Return on assets | (4.19%) | 2.76% | 2.76% |
| Return on invested capital | (19.79%) | 3.11% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack